Publicaciones en las que colabora con MARÍA SAGRARIO GÓMEZ RUIZ (21)

2017

  1. Altered striatal endocannabinoid signaling in a transgenic mouse model of spinocerebellar ataxia type-3

    PLoS ONE, Vol. 12, Núm. 4

  2. Modeling Neurodegenerative Disorders for Developing Cannabinoid-Based Neuroprotective Therapies

    Methods in Enzymology (Academic Press Inc.), pp. 175-198

2016

  1. Dysregulation of the endocannabinoid signaling system in the cerebellum and brainstem in a transgenic mouse model of spinocerebellar ataxia type-3

    Neuroscience, Vol. 339, pp. 191-209

2014

  1. Changes in CB1 and CB2 receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias

    British Journal of Pharmacology, Vol. 171, Núm. 6, pp. 1472-1489

  2. Endocannabinoid-hydrolysing enzymes in the post-mortem cerebellum of humans affected by hereditary autosomal dominant ataxias

    Pathobiology, Vol. 81, Núm. 3, pp. 149-159

2013

  1. Description of a bivalent cannabinoid ligand with hypophagic properties

    Archiv der Pharmazie, Vol. 346, Núm. 3, pp. 171-179

  2. Design and synthesis of novel cannabinoid ligands based on a 1,2,3-triazole scaffold

    Letters in Drug Design and Discovery, Vol. 10, Núm. 2, pp. 169-172

  3. Novel antiobesity agents: Synthesis and pharmacological evaluation of analogues of Rimonabant and of LH21

    Bioorganic and Medicinal Chemistry, Vol. 21, Núm. 7, pp. 1708-1716

2012

  1. Chromenopyrazoles: Non-psychoactive and Selective CB 1 Cannabinoid Agonists with Peripheral Antinociceptive Properties

    ChemMedChem, Vol. 7, Núm. 3, pp. 452-463

2010

  1. The endocannabinoid system as a target for the treatment of neuronal damage

    Expert Opinion on Therapeutic Targets, Vol. 14, Núm. 4, pp. 387-404

2009

  1. Cannabinoids, multiple sclerosis and neuroprotection

    Expert Review of Clinical Pharmacology, Vol. 2, Núm. 6, pp. 645-660

2008

  1. Cannabinoid signaling system: does it play a function in cell proliferation and migration, neuritic elongation and guidance and synaptogenesis during brain ontogenesis?

    Cell adhesion & migration, Vol. 2, Núm. 4, pp. 246-248

  2. Colocalization of CB1 receptors with L1 and GAP-43 in forebrain white matter regions during fetal rat brain development: Evidence for a role of these receptors in axonal growth and guidance

    Neuroscience, Vol. 153, Núm. 3, pp. 687-699

2007

  1. An overview on the biochemistry of the cannabinoid system

    Molecular Neurobiology, Vol. 36, Núm. 1, pp. 3-14

  2. The activation of cannabinoid receptors during early postnatal development reduces the expression of cell adhesion molecule L1 in the rat brain

    Brain Research, Vol. 1145, Núm. 1, pp. 48-55

2005

  1. Effects on development

    Handbook of Experimental Pharmacology, Vol. 168, pp. 643-656

  2. Therapeutic potential of the endocannabinoid system in the brain

    Mini-Reviews in Medicinal Chemistry, Vol. 5, Núm. 7, pp. 609-617

2004

  1. Cannabinoids and gene expression during brain development

    Neurotoxicity Research, Vol. 6, Núm. 5, pp. 389-401

2003

  1. Prenatal cannabinoid and gene expression for neural adhesion molecule L1 in the fetal rat brain.

    Brain research. Developmental brain research, Vol. 147, Núm. 1-2, pp. 201-207

2002

  1. Changes in prodynorphin and POMC gene expression in several brain regions of rat fetuses prenatally exposed to Δ9-tetrahydrocannabinol

    Neurotoxicity Research, Vol. 4, Núm. 3, pp. 211-218